Experienced in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Graeme F. Woodworth

Neurosurgery
University Of Maryland Neurosurgery Associates P A
22 S Green St, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
University Of Maryland Neurosurgery Associates P A
22 S Green St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Graeme Woodworth is a Neurosurgery provider in Baltimore, Maryland. Dr. Woodworth is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy. Dr. Woodworth is currently accepting new patients.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in MD
Hospital Affiliations
University Of Maryland Medical Center
University Of MD Baltimore Washington Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OF MARYLAND NEUROSURGERY ASSOCIATES P A
22 S Green St, Baltimore, MD 21201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Device
Study Phase: Not Applicable
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2024
Intervention Type: Drug, Device
Study Drug: Carboplatin
Study Phase: Phase 1/Phase 2
A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) in Patients With Suspected Infiltrating Glioma in the Setting of Planned Surgical Interventions
A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) in Patients With Suspected Infiltrating Glioma in the Setting of Planned Surgical Interventions
Enrollment Status: Suspended
Publish Date: August 03, 2022
Intervention Type: Device
Study Phase: Not Applicable
View 3 Less Clinical Trials

90 Total Publications

The Deformability of the Mammalian Cell Nucleus is Determined by the Identity of the Lamin Rod Domain.
The Deformability of the Mammalian Cell Nucleus is Determined by the Identity of the Lamin Rod Domain.
Journal: bioRxiv : the preprint server for biology
Published: August 08, 2025
Similar Doctors
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Joel W. Winer
Neurosurgery
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Joel W. Winer
Neurosurgery

Wellspan Medical Group

228 St Charles Way, Wellspan Neurosurgery, 
York, PA 
 (44.3 miles away)
717-812-5400
Languages Spoken:
English
See accepted insurances

Joel Winer is a Neurosurgery provider in York, Pennsylvania. Dr. Winer is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Hydrocephalus, Cervical Spondylosis, Invertebral Disc Disease, Cervical Disc Surgery, and Herniated Disc Surgery.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Robert F. Keating
Neurosurgery | Pediatrics
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Robert F. Keating
Neurosurgery | Pediatrics

Children's Hospital

111 Michigan Ave Nw, 
Washington, DC 
 (32.6 miles away)
202-476-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Keating is a Neurosurgery specialist and a Pediatrics provider in Washington, Washington, D.c.. Dr. Keating is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Craniosynostosis, Metopic Ridge, Chiari Malformation Type 1, Posterior Fossa Decompression, and Craniectomy. Dr. Keating is currently accepting new patients.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Suresh N. Magge
Neurosurgery | Pediatrics
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Suresh N. Magge
Neurosurgery | Pediatrics
111 Michigan Ave NW, Childrens Natl Med Ctr, 4th Fl West Wing, Suite 100, 
Washington, DC 
 (32.6 miles away)
202-476-3020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Suresh Magge is a Neurosurgery specialist and a Pediatrics provider in Washington, Washington, D.c.. Dr. Magge is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Craniosynostosis, Plagiocephaly, Cortical Dysplasia, Craniectomy, and Posterior Fossa Decompression. Dr. Magge is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Woodworth's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 11 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile